Condition: Recurrent High-Grade Gliomas · Recurrent Glioblastoma IDH Wildtype · Sponsor: Beijing Tiantan Hospital
This is an investigator-initiated, Phase I clinical trial. It aims to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of a novel radiopharmaceutical, \[177Lu\]Lu-DOTA-EB-RGD2, in patients with recurrent high-grade gliomas. Participants will receive the drug either via intravenous infusion or directly into the tumor cavity through a pre-implanted Ommaya reservoir (a subcutaneously placed device that allows direct access to the tumor cavity). The study employs a "3+3" dose-escalation design to determine the maximum tolerated dose (MTD). Adverse events, biodistribution, and tumor response (by MRI) will be assessed. Approximately 24 patients will be enrolled across two major Chinese medical centers: Beijing Tiantan Hospital and Peking Union Medical College Hospital.
This description comes directly from the study's public registry record.
Li'ao Wang, M.D. · +86 15001171671 · wangliao17@163.com
Deling Li, M.D. · lideling@bjtth.org
Always discuss trial participation with your own doctor first.
| Beijing Tiantan Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07655869